Methods of treating cancer using glucagon-like hormone retargeted endopeptidases

Details for Australian Patent Application No. 2010282278 (hide)

Owner Allergan, Inc.

Inventors Jacky, Birgitte P.S.; Garay, Patton E.; Molina, Yanira; Stathakis, Dean G.; Francis, Joseph; Aoki, Kei Roger; Fernandez-Salas, Ester; Steward, Lance E.; Ghanshani, Sanjiv; Hunt, Terrence J.

Agent Davies Collison Cave

Pub. Number AU-A-2010282278

PCT Pub. Number WO2011/020119

Priority 61/233,978 14.08.09 US

Filing date 16 August 2010

Wipo publication date 17 February 2011

International Classifications

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

Event Publications

15 March 2012 PCT application entered the National Phase

  PCT publication WO2011/020119 Priority application(s): WO2011/020119

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010282280-Use of IL-15 to increase thymic output and to treat lymphopenia

2010282276-Methods of treating cancer using neurotrophin retargeted endopeptidases